CA3043619A1 - Albumin-binding psma inhibitors - Google Patents

Albumin-binding psma inhibitors Download PDF

Info

Publication number
CA3043619A1
CA3043619A1 CA3043619A CA3043619A CA3043619A1 CA 3043619 A1 CA3043619 A1 CA 3043619A1 CA 3043619 A CA3043619 A CA 3043619A CA 3043619 A CA3043619 A CA 3043619A CA 3043619 A1 CA3043619 A1 CA 3043619A1
Authority
CA
Canada
Prior art keywords
compound
formula
independently
active
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043619A
Other languages
English (en)
French (fr)
Inventor
Clifford BERKMAN
Cindy CHOY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Targeted Technology LLC
Original Assignee
Cancer Targeted Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Technology LLC filed Critical Cancer Targeted Technology LLC
Publication of CA3043619A1 publication Critical patent/CA3043619A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3043619A 2016-11-23 2017-11-24 Albumin-binding psma inhibitors Pending CA3043619A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
US62/425,810 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (1)

Publication Number Publication Date
CA3043619A1 true CA3043619A1 (en) 2018-05-31

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043619A Pending CA3043619A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Country Status (8)

Country Link
US (1) US11147889B2 (enExample)
EP (1) EP3544960A1 (enExample)
JP (1) JP7167021B2 (enExample)
CN (1) CN109982998A (enExample)
BR (1) BR112019010206A2 (enExample)
CA (1) CA3043619A1 (enExample)
MX (1) MX2019005742A (enExample)
WO (1) WO2018098390A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
US20220009883A1 (en) * 2018-11-14 2022-01-13 Noria Therapeutics, Inc. Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
CA3144094A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2021177390A1 (ja) 2020-03-04 2021-09-10 日本メジフィジックス株式会社 化合物及び放射性標識化合物
US20230165979A1 (en) * 2020-05-06 2023-06-01 Cornell University Copper-containing theragnostic compositions and methods of use
JP2023552383A (ja) * 2020-12-04 2023-12-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ペプチド受容体放射性核種療法
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
AU2022228911A1 (en) * 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
EP4486756A1 (en) * 2022-03-04 2025-01-08 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
CN118496305A (zh) * 2023-02-16 2024-08-16 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
PL3222617T3 (pl) * 2009-03-19 2023-01-02 The Johns Hopkins University Związki do kierunkowania w psma i ich zastosowania
PL2739316T3 (pl) * 2011-08-05 2019-09-30 Molecular Insight Pharmaceuticals, Inc. Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty
US10011632B2 (en) * 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
JP2016537027A (ja) * 2013-11-06 2016-12-01 ソルスティス バイオロジクス，リミティッド ジスルフィド基を有するポリヌクレオチド構築物
CN105849568B (zh) 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
ES2912753T3 (es) * 2014-08-24 2022-05-27 Max Planck Gesellschaft Zur Foerderung Der Wss Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA
SI3356385T1 (sl) * 2015-09-30 2021-04-30 Deutsches Krebsforschungszentrum 18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate
RS62274B1 (sr) * 2016-03-22 2021-09-30 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
AU2017281364B2 (en) * 2016-06-23 2023-06-22 Cornell University Double targeted constructs to affect tumor kill
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Also Published As

Publication number Publication date
EP3544960A1 (en) 2019-10-02
JP2019535754A (ja) 2019-12-12
WO2018098390A1 (en) 2018-05-31
US11147889B2 (en) 2021-10-19
BR112019010206A2 (pt) 2019-09-03
CN109982998A (zh) 2019-07-05
US20200061218A1 (en) 2020-02-27
JP7167021B2 (ja) 2022-11-08
MX2019005742A (es) 2019-09-13

Similar Documents

Publication Publication Date Title
US11147889B2 (en) Albumin-binding PSMA inhibitors
AU2023203682B2 (en) Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
TWI657827B (zh) 用於正子斷層掃描之化合物
ES2657863T3 (es) Inhibidores quelados de PSMA
CA2844151C (en) Radiolabeled prostate specific membrane antigen inhibitors
AU2022219525B2 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
JP7529735B2 (ja) キレート化されたｐｓｍａ阻害剤
BR112012001260B1 (pt) Conjugados de épsilon-polilisina, seu uso, conjugado de macromolécula, e kit
TR201808820T4 (tr) Nükleer görüntüleme ve radyoterapi için şelatörlerin etkili sentezi: bileşimler ve uygulamalar.
HUE035739T2 (en) Triazine-based radiopharmaceuticals and radiological imaging agents
JP7646637B2 (ja) 画像化及び治療用組成物
AU2021427618B2 (en) Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof
US20250025582A1 (en) Ligands and their use
CN116217505A (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
US11191778B2 (en) Multifunctional linker technology containing an N4 group
US10286090B2 (en) Targeted contrast agents comprising a hydrazide functional group
JPH06504273A (ja) キレート剤
WO2005028490A1 (en) Halogenated deoxy-glucose labeled targeting molecules
CN111263768B (zh) 抗癌肽
US20220072165A1 (en) Radiodrug for diagnostic/therapeutic use in nuclear medicine and radio-guided medicine
WO2025044924A1 (zh) 靶向碳酸酐酶放射性药物
BR112023015831B1 (pt) Ligantes de proteína de ativação de fibroblastos bivalentes para aplicações de liberação direcionada, composições farmacêuticas, seus usos e métodos para preparar um conjugado
CN121930218A (zh) 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
CN121226334A (zh) 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220620

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241015

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251015

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251111

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260504